FDA
Bimzelx Beats Skyrizi 49% to 38% on ACR50 in PsA Trial
BE BOLD's Phase 3 data put a 10-point ACR50 gap between Bimzelx and Skyrizi, the $17.56B drug AbbVie built its post-Humira franchise on.
Masthead · Regulatory Intelligence Writer
Rebecca Lauren
Raleigh, NC · Joined May 2026
10+ years in regulatory strategy across biotech and small-molecule pharma. Writes the FDA enforcement and DOJ angles that move sponsor calendars. Raleigh, NC.
Stories filed
3
This year
3
Avg. read
1 min
Joined
2026
Stories by Rebecca
Legal
SEC Clears Methode Electronics After Dual Subpoenas
SEC closed its FCPA probe of Methode Electronics with no enforcement action, after two subpoenas covering executive pay and hotline tips.
FDA
Resigned: Makary, Four FDA Leaders Out in a Week
Makary's exit triggered a cascade: four more FDA leaders gone in a week, and biotech wants Richard Pazdur next. The White House hasn't said yes.
